Attractive Enough To Buy
Vanda's Positive Phase III Data In Schizophrenia Boost Shares
Vanda Pharmaceuticals Inc.'s positive Phase III results on the investigational schizophrenia drug iloperidone were well received by every measure, with the company's stock value soaring 68.7 percent Thursday, fueled by both the data and buyout rumors. (BioWorld Today)